Table 4.
Treatment characteristics of Mexican patients with endometrial carcinoma.
| Characteristic | Patients | Percentage |
|---|---|---|
| Surgery | ||
| TAH-BSO | 120 | 29.1 |
| TAH-BSO-pelvic LND | 20 | 4.9 |
| TAH-BSO-Pelvic/para aortic LND and omentum biopsy | 271 | 65.8 |
| Pelvic exenteration | 1 | .2 |
| Lymph node dissection | ||
| Pelvic | 296/412 | 71.8 |
| Para aortic | 273/412 | 66.3 |
| Chemotherapy | ||
| Yes | 59 | 14.3 |
| No | 353 | 85.7 |
| Concurrent with RT | 25/59 | 6.1 |
| Sequential chemotherapy | 31/59 | 7.5 |
| Adjuvant without RT | 3/59 | .7 |
| Chemotherapy agents used | ||
| Cisplatin/adriamicin | 15 | 3.6 |
| Cisplatin | 2 | .5 |
| CisCA regimen | 4 | 1.0 |
| Carboplatin/adriamicin/ciclophosphamide | 1 | .2 |
| PVC regimen | 3 | .7 |
| Adriamicin | 3 | .7 |
| Cisplatin/adriamicin/ciclophosphamide | 1 | .2 |
| Ciclophosphamide/adriamicin | 1 | .2 |
| Cisplatin/paclitaxel | 2 | .5 |
| Carboplatin | 22 | 5.3 |
| Carboplatin/paclitaxel | 4 | 1.0 |
| Gemcitabine | 1 | .2 |
| Hormone therapy | ||
| Yes | 10 | 2.4 |
| No | 402 | 97.6 |
| Radiotherapy | ||
| Yes | 270 | 65.53 |
| No | 142 | 34.47 |
| Pelvic EBRT | 11/270 | 4.08 |
| WART + pelvic RT + VBT | 8/270 | 2.96 |
| EBRT + VBT | 241/270 | 89.26 |
| VBT | 7/270 | 2.59 |
| Pelvic + retroperitoneum EBRT + VBT | 3/270 | 1.11 |
| Brachytherapy | ||
| Yes | 255/412 | 61.89 |
| No | 157/412 | 38.11 |
| High-dose rate | 14/255 | 5.49 |
| Low-dose rate | 241/255 | 94.51 |
TAH-BSO: total abdominal hysterectomy, TAH-BSO-LND: total abdominal histerectomy and lymph node dissection, EBRT: external beam radiotherapy, WART: whole abdominal radiotherapy, and VBT: vaginal vault brachytherapy.